Scientists develop tools to unravel gut problems in cystic fibrosis
NCT ID NCT01494909
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to create new methods to measure how well the gut digests and absorbs fats, proteins, and sugars in people with cystic fibrosis (CF). Poor digestion is a major cause of malnutrition in CF, leading to muscle weakness and worse health. The researchers will test these methods in 30 adults and children with CF and healthy volunteers to better understand gut function and improve nutritional care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
30 people
The number who actually took part.
- Started
-
Nov 2010
- Finished
-
Dec 2011
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
10 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Adult subjects with CF 1. Diagnosis of CF based on universal diagnostic criteria 2. Pancreatic insufficiency based on clinical diagnosis 3. Abnormal lipid digestion requiring pancreatic enzyme replacement therapy 4. Age is 18 years and older. 5. Admitted to UAMS for treatment of exacerbations of CF (inpatients) or under routine medical control at the CF center of UAMS 6. Clinically stable CF at the time of enrollment Healthy adults 1. Age is 18 years and older at the time of enrollment. 2. BMI between 18 and 35 kg/m2 Exclusion Criteria: Pediatric and adult CF groups 1. Unstable metabolic diseases including liver (cirrhosis) or renal disease 2. Chronic respiratory failure with cor pulmonale 3. Any other condition according to the principle investigator or study physician would interfere with proper conduct of study / safety of the patient 4. Failure to give assent / informed consent 5. Diagnosis of severe lung disease, defined as FEV1 \< 35% predicted Healthy adults * Presence of acute or chronic unstable diseases such as liver, renal, heart or lung disease * Previous surgery less than 4 weeks prior to the experiment * Recent involuntary weight loss (\>10% in the past 3 months) * Any documented autoimmune disease * Any other condition according to the principle investigator or study physician would interfere with collecting study samples * Failure to give informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cystic fibrosis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real world clinical outcomes with novel modulator therapy combinations in people with CF (RECOVER)
- Can video calls reveal how cystic fibrosis affects daily life?
- Could a blood vessel drug boost exercise capacity in cystic fibrosis?
- Could cystic fibrosis offer hidden protection against COVID-19?
- Can a 'Treatable Traits' approach unlock better care for all airway diseases?
- A smartphone tool may help cystic fibrosis patients survive the lung transplant waitlist